ReviewNeurochemical research2017
Can Neurochemical Changes of Mood Disorders Explain the Increase Risk of Epilepsy or its Worse Seizure Control?
Review in Neurochemical research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05450822 (The BrainDrugs-Epilepsy Study), which is not on this map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The BrainDrugs-Epilepsy Study: A Prospective Open-label Cohort Precision Medicine Study in Epilepsy
Who cites it
9 citing papers in PubMed.
- A nationwide study of initiation of antidepressant pharmacotherapy and the risk of seizures.Epilepsy research · 2023Article
- Directionality of the Association Between Epilepsy and Depression: A Nationwide Register-Based Cohort Study.Neurology · 2023Article
- The BrainDrugs-epilepsy study: A prospective open-label cohort precision medicine study in epilepsy.Neuroscience applied · 2023Article
- Disease Modification in Epilepsy: Behavioural Accompaniments.Current topics in behavioral neurosciences · 2022Article
- Impact of COVID-19 Lockdown, during the Two Waves, on Drug Use and Emergency Department Access in People with Epilepsy: An Interrupted Time-Series Analysis.International journal of environmental research and public health · 2021Article
- Anti-inflammatory treatment with a soluble epoxide hydrolase inhibitor attenuates seizures and epilepsy-associated depression in the LiCl-pilocarpine post-status epilepticus rat model.Brain, behavior, and immunity · 2019Article
- Environmental Enrichment and Brain Neuroplasticity in the Kainate Rat Model of Temporal Lobe Epilepsy.Journal of epilepsy research · 2019Article
- Beyond depression: The impact of executive functioning on quality of life in patients with temporal lobe epilepsy.Epilepsy research · 2019Article
- A Comprehensive Overview on Stress Neurobiology: Basic Concepts and Clinical Implications.Frontiers in behavioral neuroscience · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The existence of a bidirectional relation between mood disorders and epilepsy has been suggested by six population-based studies. Furthermore, three studies have associated a higher risk of treatment-resistant epilepsy with a history of depression preceding the onset of epilepsy. Common pathogenic mechanisms operant in depression and epilepsy may provide a possible explanation of these observations. This article reviews some of the leading pathogenic mechanisms of depression with respect to potential proconvulsant properties that may provide explanations for these phenomena.
Indexed as
Identifiers
28667464What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.